Company Profile

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE533.959.2 (+1.75 % )
PREV CLOSE (Rs.) 524.75
OPEN PRICE (Rs.) 524.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 7383
TODAY'S LOW / HIGH (Rs.)521.50 543.00
52 WK LOW / HIGH (Rs.)292 589.8
NSE536.45 11.25 (+2.14 % )
PREV CLOSE(Rs.) 525.20
OPEN PRICE (Rs.) 526.85
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 536.45 (132 )
VOLUME 327616
TODAY'S LOW / HIGH(Rs.) 521.20 555.00
52 WK LOW / HIGH (Rs.)291.6 590

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.37
TTM EPS (Rs.) 12.13
P/E Ratio 44.01
Book Value (Rs.) 45.04
Face Value (Rs.) 1
MCap (Rs. in Mn) 135924.96
Price/Earning (TTM) 39.69
Price/Sales (TTM) 13.13
Price/Book (MRQ) 11.85
PAT Margin (%) 30.57
ROCE (%) 39.15
Incorporation Year : 2018

Management Info :

Venkateswarlu Jasti - Chairman Venkateswarlu Jasti - Managing Director

Registered Office :

Address : #8-2-334 I, S D E Serene Chambers,6th Floor Road No. 5,Avenue 7, Banjara Hills ,
Hyderabad,
Telangana-500034

Phone : 040 - 2354 9414/ 3311/ 3315

Website : www.suvenpharm.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
22Sep09-22-2021$Suven Pharmaceuticals informs about investor meeting Suven Pharmaceuticals inform
Suven Pharmaceuticals has informed that it enclosed the schedule of investor meeting with the Company. Management of Suven Pharmaceuticals is participating in Ideation Series, virtual conference conducted by B&K securities, Mumbai at 4:45 to 5:30pm on 22 Sept 2021. Discussion will be on the Company specific information including Financial Results which were already in public domain.

The above information is a part of company’s filings submitted to BSE.

Suven Pharmaceuticals has informed that it enclosed the schedul..
06Aug08-06-2021$ Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Friday, The 13Th August, 2021 Board Meeting Intimation fo
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Friday, the 13th August, 2021 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and approve the following matter(s): To consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the first quarter ending June 30, 2021 and related matters. Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st July, 2021 as per PIT Code of the Company. Trading window will be opened from 17th August, 2021.
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of t..
11Jun06-11-2021$Suven Pharmaceuticals enters into agreement with CSIR-IICT Suven Pharmaceuticals enters

Suven Pharmaceuticals (SPL), CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad and CSIR-National Institute of Interdisciplinary Science & Technology, Thiruvananthapuram have entered into an agreement for the process technology transfer and manufacturing of the anti-COVID drug, Molnupiravir and 2-DG.

The agreements between the parties involve a total fee of Rs 8 lakh plus taxes for the grant of the licenses on non-exclusive basis to SPL. As per the agreement, CSIR IICT also would provide the process know how for the manufacture of new anti-COVID drug 2-DG to treat moderately and severely COVID infected patients to reduce their oxygen dependency.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

Suven Pharmaceuticals (SPL), CSIR-Indian Institute of Chemical..
11Jun06-11-2021$Suven Pharmaceuticals jumps on entering into agreement with CSIR-IICT Suven Pharmaceuticals jumps

Suven Pharmaceuticals is currently trading at Rs. 501.00, up by 20.15 points or 4.19% from its previous closing of Rs. 480.85 on the BSE.

The scrip opened at Rs. 495.20 and has touched a high and low of Rs. 514.35 and Rs. 495.20 respectively. So far 48835 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 565.00 on 26-Apr-2021 and a 52 week low of Rs. 152.50 on 12-Jun-2020.

Last one week high and low of the scrip stood at Rs. 523.90 and Rs. 460.00 respectively. The current market cap of the company is Rs. 12732.07 crore.

The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 12.45% and 27.55% respectively.

Suven Pharmaceuticals (SPL), CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad and CSIR-National Institute of Interdisciplinary Science & Technology, Thiruvananthapuram have entered into an agreement for the process technology transfer and manufacturing of the anti-COVID drug, Molnupiravir and 2-DG.

The agreements between the parties involve a total fee of Rs 8 lakh plus taxes for the grant of the licenses on non-exclusive basis to SPL. As per the agreement, CSIR IICT also would provide the process know how for the manufacture of new anti-COVID drug 2-DG to treat moderately and severely COVID infected patients to reduce their oxygen dependency.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

Suven Pharmaceuticals is currently trading at Rs. 501.00, up by..
01Jun06-01-2021$Suven Pharmaceuticals board to consider financial results & final dividend Suven Pharmaceuticals board

Suven Pharmaceuticals has informed that a Meeting of the Board of Directors of the Company will be held on June 08, 2021, to consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ending March 31, 2021; and to consider and recommend a final dividend, if any, for the financial year ending March 31, 2021. Further note that trading window for dealing in the securities of the Company is already closed from April 01, 2021 as per PIT Code of the Company. Trading window will be opened from June 11, 2021.

The above information is a part of company’s filings submitted to BSE.

Suven Pharmaceuticals has informed that a Meeting of the Board..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit814.413086.47
Gross Profit 1092.8 4139.79
Operating Profit 1203.994547.59
Net Sales 2638.0110097.19
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 20746.95 (0.93%)
M.Cap ( in Cr)
44085.82
Ajanta Pharma (BSE)
 2215.40 (2.45%)
M.Cap ( in Cr)
19171.13
Sanofi India (BSE)
 8117.95 (0.35%)
M.Cap ( in Cr)
18696.14
Mercury Laboratories (BSE)
 718.00 (3.16%)
M.Cap ( in Cr)
86.16
Coral Laboratories (BSE)
 373.00 (1.97%)
M.Cap ( in Cr)
133.26
Shareholding Pattern More
PROMOTERS 60 %
MUTUAL FUNDS/UTI 4.94 %
NON-INSTITUTION 26.16 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes